List view / Grid view
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
High-content assays using 3D objects, such as cysts or organoids, can be challenging from the perspectives of both image acquisition and image analysis.
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
Advances in genomics and structural biology are providing drug discovery scientists with more biological targets to prosecute, and greater information about each one.
Introducing the Thermo Scientific™ CellInsight™ CX7 LZR High Content Analysis System: the only imaging and analysis platform for advanced performance in screening and analysis.
Regenerative medicine has emerged as one of the major areas of modern medical therapy. Its primary objective is to restore or establish normal function through the regeneration or replacement of diseased cells, tissues or entire organs. There are a variety of methods and approaches by which this can be achieved.…
The pursuit of improved R&D productivity rates coupled with decreased cycle times has dominated pharmaceutical discourse in recent years.
Bioactivity profiling has been traditionally used to assess the selectivity of new drug candidates in the context of target-based approaches, where pharmacological selectivity is a key requirement.
This In-Depth Focus reviews the history of cancer treatments, looks at improving the translation of disease biology though phenomics, and considers how to enhance cell bioprocessing through cell-based combinatorial culture.
In this issue: the positive impact of genomics on drug discovery, development and deployment, the confluence of biology and technology, and Artificial Intelligence: harnessing the potential to drive progress in drug discovery promises much for phenotypic drug discovery
How to perform successful long term live cell imaging in a high-content analysis system.
A new diagnostic test developed by researchers at UC San Diego shows promise for detecting pancreatic cancer earlier...
Extension includes new project to phenotype Parkinson’s disease models and the continuation of LRRK2 research.
Addition of high-throughput technologies and expanded pharmacokinetic services enhances existing support for small molecule drug discovery.
Researchers are reporting an innovative new method to screen for potential cancer drugs...
27 April 2018 | By TECAN
ABOUT THIS WEBINAR: In this two-part webinar, both automation of P450 (CYP) assays and the automatisation of cellular differentiation processes and compound testing using human induced pluripotent stem cells based assays was covered. Metabolism of drugs is a key factor in compound toxicity, and automated assays which monitor inhibition or…
